Categories: News

Audacious Inquiry Joins Health Level 7 International (HL7®) and Integrating the Healthcare Enterprise (IHE) to Advance Interoperability Standards

BALTIMORE, April 8, 2019 /PRNewswire/ — Audacious Inquiry (Ai), an industry-leading health information technology and policy company, announced today that it has joined Health Level Seven International (HL7®), and Integrating the Healthcare Enterprise (IHE) as organizational members.

HL7 is recognized as a leading standards-developing organization, dedicated to providing a comprehensive framework that supports global health data interoperability. Their FHIR® APIs, C-CDA® implementation guide, and Version 2 and Version 3 standards are widely implemented to advance the exchange of electronic health records. Similarly, IHE manages a set of technical guidelines which members can implement to demonstrate improved health data accessibility. IHE’s Cross-Enterprise Document Sharing (XDS), patient location and identity management, and data exchange and security specifications facilitate the transfer of electronic health records.

By joining both organizations, Ai will lend insight and will influence the strategic direction of HL7 and IHE.

Scott Afzal, President of Ai stated, “By joining HL7 and IHE, we will deepen our engagement in the development of standards that are advancing interoperability in healthcare. We believe strongly in the impact of standards development and interoperability efforts on improving healthcare outcomes, and Ai is committed to contributing to this work.” He continued, “Our modular, cloud-based software solutions will continue to reflect our depth of familiarity with standards development.”

Ai’s Encounter Notification Service® (ENS®) is an event driven care coordination system that provides real-time updates to participating organizations. To date, over two thousand clinical organizations, health plans, and public health organizations across ten states subscribe to over 32 million patients, by way of partnerships with HIOs, Hospital Associations, and government agencies. Over 6 million notifications a month are delivered by Ai, helping reduce readmissions, improve care outcomes, and lower costs.   

One of Ai’s first contributions will be its HL7 Version 2 to FHIR mappings for its data aggregation and deduplication pipeline, to assist with the HL7 V2 to FHIR project.

For further information, contact media@ainq.com.

About Audacious Inquiry
Audacious Inquiry (Ai) is an industry-shaping health information technology and policy company that provides bold solutions for connected healthcare. Nationally recognized for its work to facilitate health data interoperability, Ai is a trusted partner to CMS, ONC, state Hospital Associations and Medicaid agencies across the country; and, delivers a SaaS technology platform that is the catalyst for health information exchange across 10 states. By pioneering technology that enables statewide health information exchange, Ai is raising the bar for how health data is shared, managed, and protected.

View original content to download multimedia:http://www.prnewswire.com/news-releases/audacious-inquiry-joins-health-level-7-international-hl7-and-integrating-the-healthcare-enterprise-ihe-to-advance-interoperability-standards-300826224.html

SOURCE Audacious Inquiry

Staff

Recent Posts

HeartBeam to Attend JP Morgan 2025 Annual Healthcare Conference

HeartBeam system was recently cleared by US Food and Drug Administration (FDA) for comprehensive arrhythmia…

48 minutes ago

Glaukos Submits New Drug Application to U.S. FDA for Epioxa™

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused…

49 minutes ago

The National Children’s Cancer Society Awarded $1,000 Grant From Kars4Kids

This generous grant will directly benefit the NCCS's Beyond the Cure Ambassador Scholarship Program, which…

52 minutes ago

Honeycomb Clinic Positions for Public Offering

Medical Co-working space challenges broken healthcare system. HOUSTON, TEXAS / ACCESSWIRE / December 23, 2024…

52 minutes ago

Ensysce Biosciences Regains Full Compliance with Nasdaq

SAN DIEGO, CALIFORNIA / ACCESSWIRE / December 23, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce"…

52 minutes ago

Telomir Pharmaceuticals Confirms Copper Binding Capabilities of Telomir-1 and Expands Pipeline Into Wilson’s Disease

MIAMI, FL / ACCESSWIRE / December 23, 2024 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), or the…

52 minutes ago